Abstract
Most inflammatory disorders are becoming more prevalent, especially in Western countries. The proinflammatory cytokine tumor necrosis factor-α (TNF) plays a prominent role in many of these inflammatory disorders. We have previously shown that SPRET/Ei mice exhibit an extreme and dominant resistance to high doses of TNF. In this report, we investigate the response of heterozygous (C57BL/6xSPRET/Ei)F1 mice in different models of inflammatory diseases. Compared with C57BL/6 mice, (B × S)F1 mice are protected against TNF-induced arthritis and are partially protected against allergic asthma in an ovalbumin-induced model. However, these mice display complete susceptibility to TNF-induced inflammatory bowel disease. These results indicate that the SPRET/Ei genome harbors potent dominant antiinflammatory genes that might be relevant for the treatment of certain chronic inflammatory diseases. It is very well possible that different genes are implicated in the different models.
Similar content being viewed by others
Abbreviations
- OVA:
-
chicken ovalbumin
- PBS:
-
phosphate buffered saline
- TNF:
-
tumor necrosis factor alpha
- RA:
-
rheumatoid arthritis
- IBD:
-
inflammatory bowel disease
- TD:
-
tissue destruction
- BAL:
-
brochoalveolar lavage
- BALF:
-
BAL fluid
- B:
-
C57BL/6
- S:
-
SPRET/Ei
References
InstitutionalAuthorNameAnonymous (2000) ArticleTitleAsthma Nat Biotechnol 18 IssueIDSuppl IT10-1
DH Broide G Stachnick D Castaneda J Nayar P Sriramarao (2001) ArticleTitleInhibition of eosinophilic inflammation in allergen-challenged TNF receptor p55/p75-and TNF receptor p55-deficient mice Am J Respir Cell Mol Biol 24 304–311 Occurrence Handle1:CAS:528:DC%2BD3MXitleltb4%3D Occurrence Handle11245629
G Kollias E Douni G Kassiotis D Kontoyiannis (1999a) ArticleTitleThe function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Ann Rheum Dis 58 IssueIDSuppl 1 132–139
G Kollias E Douni G Kassiotis D Kontoyiannis (1999b) ArticleTitleOn the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Immunol Rev 169 175–194 Occurrence Handle1:CAS:528:DyaK1MXltlOgsLo%3D
D Kontoyiannis M Pasparakis TT Pizarro F Cominelli G Kollias (1999) ArticleTitleImpaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies Immunity 10 387–398 Occurrence Handle10.1016/S1074-7613(00)80038-2 Occurrence Handle1:CAS:528:DyaK1MXitlalsro%3D Occurrence Handle10204494
D Kontoyiannis G Boulougouris M Manoloukos M Armaka M Apostolaki et al. (2002) ArticleTitleGenetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn’s-like inflammatory bowel disease J Exp Med 196 1563–1574 Occurrence Handle10.1084/jem.20020281 Occurrence Handle1:CAS:528:DC%2BD38XpslWlurY%3D Occurrence Handle12486099
M Korsgren JS Erjefalt O Korsgren F Sundler CG Persson (1997) ArticleTitleAllergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice J Exp Med 185 885–892 Occurrence Handle10.1084/jem.185.5.885 Occurrence Handle1:CAS:528:DyaK2sXhsFKgurs%3D Occurrence Handle9120394
S Kroesen AF Widmer A Tyndall P Hasler (2003) ArticleTitleSerious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy Rheumatology 42 617–621
PE Lipsky DM Heijde Particlevan der EW St. Clair DE Furst FC Breedveld et al. (2000) ArticleTitleInfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 1594–1602 Occurrence Handle10.1056/NEJM200011303432202 Occurrence Handle1:CAS:528:DC%2BD3cXovVeltLk%3D Occurrence Handle11096166
R Maini EW St. Clair F Breedveld D Furst J Kalden et al. (1999) ArticleTitleInfliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932–1939 Occurrence Handle10.1016/S0140-6736(99)05246-0 Occurrence Handle1:CAS:528:DC%2BD3cXit1Oquw%3D%3D Occurrence Handle10622295
DN Mannel B Echtenacher (2000) ArticleTitleTNF in the inflammatory response Chem Immunol 74 141–161 Occurrence Handle1:CAS:528:DC%2BD3cXntFKks7c%3D Occurrence Handle10608086
LW Moreland MH Schiff SW Baumgartner EA Tindall RM Fleischmann et al. (1999) ArticleTitleEtanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann Intern Med 130 478–486 Occurrence Handle1:CAS:528:DyaK1MXitFChs7Y%3D Occurrence Handle10075615
D O’Neil L Steidler (2003) ArticleTitleCytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel disease Adv Exp Med Biol 520 252–285 Occurrence Handle1:CAS:528:DC%2BD3sXns1ersrg%3D Occurrence Handle12613583
A Persidis (1999) ArticleTitleArthritis drug discovery Nat Biotechnol 17 726–728 Occurrence Handle10.1038/10954 Occurrence Handle1:CAS:528:DyaK1MXksFehtLc%3D Occurrence Handle10409361
J Rothe W Lesslauer H Lotscher Y Lang P Koebel et al. (1993) ArticleTitleMice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes Nature 364 798–802 Occurrence Handle10.1038/364798a0 Occurrence Handle1:CAS:528:DyaK3sXmtVWmurw%3D Occurrence Handle8395024
DG Rudmann MW Moore JS Tepper MC Aldrich JW Pfeiffer et al. (2000) ArticleTitleModulation of allergic inflammation in mice deficient in TNF receptors Am J Physiol Lung Cell Mol Physiol 279 L1047–1057 Occurrence Handle1:CAS:528:DC%2BD3cXptFSksbc%3D Occurrence Handle11076794
WJ Sandbrn SB Hanauer (1999) ArticleTitleAntitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 119–133 Occurrence Handle10338381
J Staelens B Wielockx L Puimege F Roy ParticleVan JL Guenet et al. (2002) ArticleTitleHyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy Proc Natl Acad Sci USA 99 9340–9345 Occurrence Handle10.1073/pnas.142293699 Occurrence Handle1:CAS:528:DC%2BD38XlsVGgsbs%3D Occurrence Handle12089334
PS Thomas (2001) ArticleTitleTumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma Immunol Cell Biol 79 132–140 Occurrence Handle10.1046/j.1440-1711.2001.00980.x Occurrence Handle1:STN:280:DC%2BD3M7ms1ensw%3D%3D Occurrence Handle11264706
DT Umetsu JJ McIntire O Akbari C Macaubas RH DeKruyff (2002) ArticleTitleAsthma: an epidemic of dysregulated immunity Nat Immunol 3 715–720 Occurrence Handle10.1038/ni0802-715 Occurrence Handle1:CAS:528:DC%2BD38Xls1Snuro%3D Occurrence Handle12145657
P Vassalli (1992) ArticleTitleThe pathophysiology of tumor necrosis factors Annu Rev Immunol 10 411–452 Occurrence Handle10.1146/annurev.iy.10.040192.002211 Occurrence Handle1:CAS:528:DyaK38XltV2ntLg%3D Occurrence Handle1590993
ME Weinblatt JM Kremer AD Bankhurst KJ Bulpitt RM Fleischmann et al. (1999) ArticleTitleA trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 253–259 Occurrence Handle10.1056/NEJM199901283400401 Occurrence Handle1:CAS:528:DyaK1MXht1Wqsbk%3D Occurrence Handle9920948
Acknowledgments
This work was supported in part by the Fonds voor Wetenschappelijk Onderzoek–Vlaanderen (Grant G023698N), the Interuniversitaire attractiepolen, and FORTIS assurancies. J.S., T.M., and A.V. are fellows with the Vlaamse Instituut voor de bevordering van het Wetenschappelijk–Technologisch Onderzoek in de Industrie.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Staelens, J., Puimège, L., Mahieu, T. et al. Response of TNF-hyporesponsive SPRET/Ei mice in models of inflammatory disorders. Mamm Genome 15, 537–543 (2004). https://doi.org/10.1007/s00335-004-3002-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00335-004-3002-z